Comparative Pharmacology
Head-to-head clinical analysis: DOXYCYCLINE HYCLATE versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCYCLINE HYCLATE versus VIBRAMYCIN.
DOXYCYCLINE HYCLATE vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline hyclate is a bacteriostatic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-angiogenic properties.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily. For severe infections or certain indications, 100 mg every 12 hours.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
18-24 hours in patients with normal renal function; may increase to 24-48 hours in renal impairment; clinical context: allows once- or twice-daily dosing.
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-30% eliminated in feces via biliary secretion and nonbiliary routes; the remainder is metabolized. Enterohepatic circulation contributes to prolonged half-life.
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic